Bifogade filer
Simris Group AB Announces Positive Results from Ongoing Antibody-Drug Conjugate (ADC) Study with Nuvisan
Kurs
+8,70%
Likviditet
0,30 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-25 | 08:00 | Bokslutskommuniké 2025 |
| 2025-11-12 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-13 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-15 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2025-05-14 | - | Årsstämma |
| 2025-05-14 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-26 | - | Bokslutskommuniké 2024 |
| 2025-01-20 | - | Extra Bolagsstämma 2025 |
| 2024-11-13 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-14 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-30 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2024-05-29 | - | Årsstämma |
| 2024-05-15 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-05 | - | Extra Bolagsstämma 2024 |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-12-20 | - | Extra Bolagsstämma 2023 |
| 2023-11-08 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-29 | - | Årsstämma |
| 2023-05-16 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2023-05-08 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-11-09 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-17 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-16 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2022-05-13 | - | Årsstämma |
| 2022-05-13 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-08 | - | Extra Bolagsstämma 2022 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-18 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-10 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2021-05-07 | - | Årsstämma |
| 2021-05-07 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-16 | - | Bokslutskommuniké 2020 |
| 2020-11-10 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-05 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2020-06-04 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-12-19 | - | Extra Bolagsstämma 2019 |
| 2019-11-05 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-13 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-09 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2019-05-08 | - | Årsstämma |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-12 | - | Bokslutskommuniké 2018 |
| 2018-11-20 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2018-07-25 | - | Extra Bolagsstämma 2018 |
| 2018-05-09 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2018-05-08 | - | Årsstämma |
| 2018-05-08 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-20 | - | Bokslutskommuniké 2017 |
| 2017-11-21 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-22 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-11 | - | Årsstämma |
| 2017-05-11 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-22 | - | Bokslutskommuniké 2016 |
| 2016-11-11 | - | Kvartalsrapport 2016-Q3 |
| 2016-09-21 | - | Extra Bolagsstämma 2016 |
| 2016-08-24 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-18 | - | Kvartalsrapport 2016-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Handel & varor |
| Industri | Dagligvaror |
Simris Group AB’s wholly owned subsidiary, Simris Biologics GmbH, today announced important progress in its ongoing preclinical study with Nuvisan, a leading European contract research and development organization.
Three proprietary Microcystin (MC)-based payloads were successfully generated in ADC format and evaluated in in-vitro efficacy studies. In two independent trials, one of the ADC variants demonstrated full-blown toxicity against the corresponding antigen-expressing cancer cell line, indicating complete elimination of cancer cells in response to treatment.
This payload candidate, now designated SIMRIS-121, having exhibited excellent potent in-vitro activity, will proceed to the next stage of the Nuvisan study—a dose-escalation in-vivo study to determine the maximum tolerated dose (MTD) of the ADC in mice.
“This is a significant milestone for our Microcystin ADC program,” said Dr. Alexis Roberts-McIntosh, CEO of Simris Group AB. “The clear demonstration of full cytotoxicity in one of our MC-ADC candidates confirms the therapeutic potential of our cyanobacterial payload platform. Together with Nuvisan’s deep expertise in preclinical development, we are advancing rapidly toward in-vivo validation.”
These results further support Simris’ mission to develop novel, cyanobacteria-derived toxin payloads with improved therapeutic windows and differentiated mechanisms of action for next-generation ADCs.
For more information about Simris Biologics, visit: https://simrisbiologics.com
For more information about Nuvisan, visit: https://www.nuvisan.com
Contact Details:
Dr Alexis Roberts-McIntosh
CEO Simris Group AB
Email: ir@simris.com
Mobile: +44 (0) 7940 585298
www.simrisgroup.com
About Simris Group AB (PUBL):
Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics.
Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.
Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.